Background: This retrospective study evaluate the survival effects of metronomic 35 maintenance therapy with fluoropyrimidine in patients with stage III colorectal cancer (CRC) 36 according to epidermal growth factor receptor (EGFR) expression. Methods: We enrolled 197 patients 37 with stage III CRC who had undergone radical resection and FOLFOX regimen adjuvant 38 chemotherapy. The clinicopathological features and effects of metronomic maintenance therapy on 39 survival according to treatment group and EGFR expression were analyzed. By conducting an in vitro 40 Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 4
. EGFR expression was revealed to be an independent prognostic factor for both DFS (p = 143 0.027; hazard ratio [HR], 1.914; 95% CI, 1.076-3.405) and OS (p = 0.001; HR, 4.417; 95% CI, 1.813-144 10.761). Similarly, metronomic maintenance therapy with capecitabine was revealed to be an 145 independent prognostic factor for both DFS (p < 0.001; HR, 3.351; 95% CI, 2.000-5.614) and OS (p = 146 0.001; HR, 3.186; 95% CI, 1.631-6.222).
147
A Kaplan-Meier survival analysis indicated that the patients in the FOLFOX group had 148 significantly worse DFS (p < 0.001) and OS (p = 0.001) compared with those in the FOLFOXC group 149 ( Fig. 2A and 2B ). The median DFS periods of the patients in the FOLFOX and FOLFOXC groups were 150 16.7 and 57.9 months (p < 0.001), respectively, whereas the median OS periods of the patients in the 151 FOLFOX and FOLFOXC groups were 50.3 and 68.7 months (p = 0.001), respectively. The 5-year DFS 152 rates were 43% and 71% for the FOLFOX and FOLFOXC groups, respectively. The 5-year OS rates 153 were 58% and 84% for the FOLFOX and FOLFOXC groups, respectively. We also performed 154 subgroup analyses according to EGFR expression and treatment group, and we found no significant 155 differences in the DFS and OS of the EGFR-negative patients between the FOLFOX and FOLFOXC 156 groups ( Fig. 2C and 2D) ; however, we observed significant differences in the DFS ( Fig. 2E) By combining EGFR expression and treatment group, we performed a univariate analysis using 171 a logistic regression model to determine the predictive factors for postoperative relapse and mortality 172 (Table 4 ). We found that the EGFR-positive patients in the FOLFOX group had a higher risk of 173 postoperative relapse and mortality than did the EGFR-negative patients in the FOLFOXC group (p 174 < 0.001; OR, 5.429; 95% CI, 2.224-13.250 vs. p = 0.001; OR, 6.323; 95% CI, 2. 175-18.383, respectively).
175
The risks of postoperative relapse and mortality were not significantly different among the other 176 three groups of patients.
177
Our Kaplan-Meier survival analysis revealed that the EGFR-positive patients in the FOLFOX 178 group had significantly poorer DFS and OS than did the EGFR-negative patients in the FOLFOXC 179 group (p < 0.001; p < 0.001; Fig. 2G To analyze the suppressive effects of 5-FU (Sigma-Aldrich, Gillingham, UK) on the proliferation 192 of the control and EGFR knockout Caco2 cells, we performed the MTS assay to determine the in vitro 193 viability of scrambled control and EGFR knockout Caco2 cells at 0, 24, 48, and 72 hours after 5-FU
194
(Sigma-Aldrich, Gillingham, UK) treatment. We observed that the EGFR knockout Caco2 cells 195 exhibited significantly lower viability at 24 (*p < 0.05; -11.3%), 48 (**p < 0.001; -28.6%) and 72 (**p < 196 0.001; -32%) hours after 5-FU treatment compared with the control cells ( Fig. 3B ). These results
197
indicate that the EGFR knockout Caco2 cells were more sensitive to the antiproliferative effects of 5-
198
FU than the scrambled control Caco2 cells. (Fig. 3D ). The tumors were palpable at 28 days after inoculation 209 and were allowed to grow for 61 days ( Fig. 3E and 3F ). On day 35, scrambled control and EGFR 6 of 23 knockout groups were randomly divided into 5-FU-treated and 5-FU-non-treated groups. The mice 211 were treated according to their allocated treatment groups, and tumor burden was quantitated. We 212 found that the mice injected with the EGFR knockout Caco2 cells had significantly smaller tumors 213 than did those injected with the scrambled control Caco2 cells (p = 0.033) on day 38. The tumors were 214 the smallest in the 5-FU-treated EGFR knockout group on day 61 ( Fig. 3E and 3F ). These results 215 provide evidence that EGFR knockout enhanced the antiproliferative effects of 5-FU in vivo. 
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group than in the FOLFOXC group. Using univariate and multivariable analyses, we observed that 392 metronomic maintenance therapy with capecitabine was an independent and favorable predictive 393 factor for reduced postoperative relapse and mortality (p = 0.001 and p = 0.013, respectively). Using
394
Kaplan-Meier survival analysis, we also observed that metronomic maintenance therapy with 395 capecitabine was an independent prognostic factor for both DFS and OS (p < 0.001 and p = 0.001, 396 respectively).
397
Lymphovascular invasion is a major poor prognostic factor in patients with CRC [22] [23] [24] [25] [26] .
398
Although lymphovascular invasion was more common in the FOLFOXC group than in the FOLFOX 
535
Data were showed as a percentage of wound closure compared to initial wound. 
540
The tumor size (cm 3 ) was measured thrice a week and calculated according to the formula:
541
(length×width 2 )/2. Following 4 weeks after transplantation, 5-FU (10 mg/Kg) was administrated by 542 intraperitoneal injection thrice a week for 3 weeks. Animals were scarified at 8 weeks after injection 543 of tumor cells. To perform the in vivo study, we followed the protocols approved by the Institutional 
557
In conclusion, we demonstrated that metronomic maintenance therapy with capecitabine could 558 significantly improve the prognoses of patients with stage III CRC following radical resection and 559 FOLFOX adjuvant chemotherapy. Moreover, the effects of prognosis improvement are noteworthy 560 in patients with positive EGFR expression. However, a prospective, randomized clinical trial is 561 necessary to verify the results of the present study.
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